Our study demonstrates for the first time that subtype-specific HERV-K102-Env is a novel immunosuppressive serum cancer biomarker that correlates with tumor markers and can be used to assess the state of immune dysfunction and the staging of cancer in cancer patients. Here, ERVW-1 is linked to cancer.